Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia and thrombosis

Annals of Thoracic Surgery

Volumn 70, Issue 6, 2000, Pages 2173-2181

  Follis, Fabrizio ^a,b   Schmidt, Carlos A ^a,b  

^a UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

^b Lutheran Medical Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANCROD; APROTININ; ARACHIDONIC ACID; ARGATROBAN; CYCLIC AMP; DALTEPARIN; DANAPAROID; DIPYRIDAMOLE; ENOXAPARIN; FIBRINOGEN; HEPARIN; HIRUDIN; HIRUGEN; HIRULOG; ILOPROST; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; PHENYLEPHRINE; PHOSPHOLIPASE A2; PROSTAGLANDIN D2; TEDELPARIN; THROMBOXANE A2;

ANTICOAGULATION; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS SURGERY; DRUG CHOICE; DRUG HALF LIFE; HEART VALVE REPLACEMENT; HEMOSTASIS; HEPARINIZATION; HUMAN; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; SURGICAL RISK; THROMBOCYTOPENIA; THROMBOSIS;

ANTICOAGULANTS; BLOOD COAGULATION TESTS; CARDIOPULMONARY BYPASS; HEPARIN; HUMANS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0034529253     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(00)01329-1     Document Type: Article

References (90)

1. User's guides to the medical literature. VI. How to use an overview. Evidence-based medicine working group
2. Guidelines for reading literature reviews
3. Heparin-induced thrombocytopenia in patients who undergo open heart surgery
4. Heparin-induced thrombocytopenia in open heart surgical patients: Sequelae of late recognition
5. Complications from heparin-induced thrombocytopenia in patients undergoing cardiopulmonary bypass
6. Heparin-associated thrombocytopenia: Observations on the mechanism of platelet aggregation
7. Anticoagulation hemostasis and blood preservation
8. Thrombocytopenia associated with heparin-coated catheters in patients with heparin-associated antiplatelet antibodies
9. Thrombosis after the use of a heparin-coated cardiopulmonary bypass circuit in a patient with heparin-induced thrombocytopenia
10. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia
11. Clinical usefulness of testing for a heparin-dependent platelet-aggregating factor in patients with suspected heparin-associated thrombocytopenia
12. A diagnostic test for heparin-induced thrombocytopenia
13. Heparin-associated thrombocytopenia: Isolation of the antibody and characterization of a multimolecular PF4-heparin complex as the major antigen
14. Evaluation of a low molecular weight heparin as an anticoagulant in a model of cardiopulmonary bypass surgery
15. Low-molecular-weight heparin in extracorporeal circulation
16. A new approach in monitoring recombinant hirudin during cardiopulmonary bypass
17. Protamine reversal of anticoagulation achieved with a low molecular weight heparin: The effects on eicosanoids, clotting and complement factors
18. Cardiopulmonary bypass with a low-molecular-weight heparin fraction (enoxaparin) in a patient with a history of heparin-associated thrombocytopenia
19. Heparin-induced thrombocytopenia: Studies with a new low molecular weight heparinoid, Org 10172
20. Org 10172: A low molecular weight heparinoid anticoagulant with a long half-life in man
21. Anticoagulation and hemostasis in cardiac surgical patients
22. Assay of heparin in plasma using a chromogenic substrate for activated factor X
23. "Heparin-free" cardiopulmonary bypass: First reported use of heparinoid (Org 10172) to provide anticoagulation for cardiopulmonary bypass?
24. A randomized blind study comparing standard heparin and a new low molecular weight heparinoid in cardiopulmonary bypass surgery in dogs
25. Heparinless cardiopulmonary bypass revisited: A newer strategy to avoid heparin-related bleeding using dermatan sulfate
26. Is heparin the ideal anticoagulant for cardiopulmonary bypass? Dermatan sulphate may be an alternate choice
27. Pharmacodynamics of chimeric glycoprotein IIb/IIIa integrin antiplatelet antibody Fab 7E3 in high risk coronary angioplasty
28. Biologic effects of recombinant hirudin (CGP 39393) in human volunteers
29. Monitoring anticoagulant therapy by activated partial thromboplastin time: Hirudin assessment. An evaluation of native blood and plasma assays
30. Monitoring of recombinant hirudin: Assessment of a plasma-based ecarin clotting time assay
31. Quantitative determination of hirudin in blood and body fluids
32. Recombinant hirudin as an antithrombotic agent
33. Evaluation of CGP 39393 as the anticoagulant in cardiopulmonary bypass operation in a dog model
34. Comparison of recombinant hirudin and heparin as an anticoagulant in a cardiopulmonary bypass model
35. Potential use of recombinant hirudin as an anticoagulant in a cardiopulmonary bypass model
36. Recombinant r-hirudin as a potential anticoagulant in open heart surgery: Studies in a pig model
37. Recombinant desulfatohirudin as a substitute for heparin during cardiopulmonary bypass
38. Hirudin for cardiopulmonary bypass in patients with heparin-induced thrombocytopenia: Importance of preoperative renal function
39. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass: Assessment of the whole blood ecarin clotting time
40. Argatroban as anticoagulant in cardiopulmonary bypass surgery
41. Pilot study of the efficacy of a thrombin inhibitor for use during cardiopulmonary bypass
42. The proteolytic action of Irvine on human fibrinogen
43. Ancrod (Arvin ®) as an alternative to heparin anticoagulation for cardiopulmonary bypass
44. Hematologic changes in a patient with heparin-induced thrombocytopenia who underwent cardiopulmonary bypass after ancrod defibrinogenation
45. Arvin anticoagulant for prolonged extracorporeal membrane oxygenation
46. Defibrinogenation as an alternative to heparinization during prolonged extracorporeal circulation in the dog
47. Selective anticoagulation with active site-blocked factor IXa suggests separate roles for intrinsic and extrinsic coagulation pathways in cardiopulmonary bypass
48. Heparinless cardiopulmonary bypass using active site blocked factor IXa: A preliminary study in the dog
49. Can heparin cause adult respiratory distress syndrome by a similar mechanism as heparin-associated thrombocytopenia?
50. Transient global amnesia associated with acute heparin-induced thrombocytopenia
51. Acute adrenal insufficiency secondary to heparin-induced thrombocytopenia-thrombosis syndrome
52. Heparin-associated thrombocytopenia syndrome: An underestimated etiology of adrenal hemorrhage
53. Bilateral adrenal hemorrhage associated with heparin-induced thrombocytopenia
54. Adrenal hemorrhagic necrosis related to heparin-associated thrombocytopenia
55. White clot syndrome associated with renal failure
56. Glycoprotein IIb/IIIa inhibitors can prevent heparin-mediated platelet activation in heparin-induced thrombocytopenia
57. Is bleeding risk increased in patients undergoing urgent coronary bypass surgery following abciximab? Scientific Conference and Abstract News (SCAN)
58. Cardiopulmonary bypass with a low-molecular-weight heparin fraction
59. Extracorporeal circulation in a patient with heparin-induced thrombocytopenia
60. Iloprost (ZK36374), a new prostacyclin analogue, permits open cardiac operation in patients with heparin-induced thrombocytopenia
61. Management of patients with heparin-induced thrombocytopenia requiring cardiopulmonary bypass
62. Extracorporeal circulation in a patient with heparin-induced thrombocytopenia
63. Heparin-associated thrombocytopenia: Alternative managements
64. Prevention of heparin-induced thrombocytopenia during open heart surgery with iloprost (ZK36374)
65. Management of patients with heparin-associated thrombocytopenia and thrombosis requiring cardiac surgery
66. Heparin-associated thrombocytopenia: Management of patients for open heart surgery. Case reports describing the use of iloprost
67. Surgical management of heparin-associated thrombocytopenia: Strategies in the treatment of venous and arterial thromboembolism
68. Ancrod anticoagulation for cardiopulmonary bypass in heparin-induced thrombocytopenia and thrombosis
69. Heparin-induced thrombocytopenia: A case report
70. Intraoperative management of patients with heparin-induced thrombocytopenia
71. Heparin-associated thrombocytopenia treated with iloprost
72. The use of a low molecular weight heparinoid (Org 10172) for extracorporeal procedures in patients with heparin dependent thrombocytopenia and thrombosis
73. Orgaran in heparin-induced thrombocytopenia
74. Iloprost (Ilomédine ®) et circulation extracorporelle avec héparinisation conventionnelle chez un patient ayant une thrombopénie à l'héparine
75. Heparin-induced thrombocytopenia (HIT). An overview of 230 patients treated with orgaran (Org 10172)
76. Heparina de bajo peso molecular en un paciente con trombocitopenia inducida por heparina y tratado con una derivación cardiopulmonar
77. Heparinless cardiopulmonary bypass with ancrod
78. Normal activated clotting time despite adequate anticoagulation with ancrod in a patient with heparin-associated thrombocytopenia and thrombosis undergoing cardiopulmonary bypass
79. 1 and aspirin
80. Recombinant hirudin as an anticoagulant in open-heart surgery: A case report
81. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: Successful for aortic valve replacement in man
82. Heparin-induced thrombocytopenia and heart operation: Management with tedelparin
83. Cardiopulmonary bypass for heparin-induced thrombocytopenia: Management with a heparin bonded circuit and enoxaparin
84. Cardiopulmonary bypass in patients with heparin-induced thrombocytopenia using Org 10172
85. A case report on the use of recombinant hirudin as an anticoagulant for cardiopulmonary bypass in open heart surgery
86. Orgaran (Org 10172) for cardiopulmonary bypass in heparin-induced thrombocytopenia: Role of adjunctive plasmapheresis
87. Recombinant hirudin as anticoagulant in cardiac surgery: Experiences with eleven patients
88. Orgaran anticoagulation for cardiopulmonary bypass in patients with heparin induced thrombocytopenia
89. The combined use of iloprost and danaparoid in the surgical management of a patient with chronic thromboembolic pulmonary hypertension and heparin-induced thrombocytopenia